OncoPharm

Did lenalidomide maintenance in multiple myeloma just get limited to 2 years?

Endurance Trial, Part 2: https://www.nejm.org/doi/full/10.1056/NEJMoa2600157

Learning Oncology Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm

We are a decade into the CAR-T era, and what to long term outcomes look like with tisagenlecleucel in B-cell lymphomas?

Orca-T is approved, an allogenic cocktail of stem & progenitor cells, Tregs, and then conventional T-cells. Neato.

Polar-Go! or PolARGo?

And the concept of T-cell "stemless" is intriguing with possibilities: DOI: 10.1056/NEJMcibr2601002
Learning Oncology Companion:https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm

This week we discuss a new approval for pabociclib in HER2-positive disease based on the PATINA trial as well as the use of sacituzumab govitecan + pembrolizumab in TNBC, recently approved based on the ASCENT04/KEYNOTED19 trial.

And the concept of T-cell "stemless" is intriguing with possibilities: DOI: 10.1056/NEJMcibr2601002
Learning Oncology Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm

Lots of bite-size updates in this episode.

Capitello-281: capivasertib + abiraterone (+ prednisone + ADT)
Adjuvant Belzutifan + Pemroblizumab is FDA approved
Durvalumab approved with BCG for non-muscle invasive bladder cancer
Insightful commentary: https://doi.org/10.1200/JCO-25-02670
Talquetamab + Durvaluamb - a new safety signal?

Learning Oncology Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm

ASCO 2026 is a wrap, and we needed an extra week to digest it all! Here the review list:
1. RASolute 302 - daraxonrasib and its standing ovation

2. MajesTEC-9 - 2L teclistamab in multiple myeloma in patient population 100% exposed to CD-38 targeting drugs

3. Initsmeran autogene + pembrolizumab in resected melanoma. Only a Phase 2 study, but super promising and exciting use of personalized medicine using mRNA technology

4. Libretto-043 - adjuvant selpercatinib in RET-fusion positive NSCLC following resection and platinum-based chemotherapy (in most of these patients)

5. PROTEUS - meh

6. SARC041 - Phase study of abemaciclib vs. placebo in dedifferntiated liposarcoma. The placebo did very poorly

7. CROWN at 7-years continues to offer an enticing PFS plateau with lorlatinib use in advanced ALK rearrangement+ NSCLC

The Learning Oncology Companion from KelleyCPharmD:
https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm